Relmada Therapeutics Company Profile (NASDAQ:RLMDD)

About Relmada Therapeutics

Relmada Therapeutics logo

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RLMDD
  • CUSIP:
Key Metrics:
  • Previous Close: $4.72
  • 50 Day Moving Average: $3.11
  • 200 Day Moving Average: $5.64
  • 52-Week Range: $2.00 - $19.90
  • Trailing P/E Ratio: 9.22
  • Foreward P/E Ratio: -2.24
  • P/E Growth: 0.00
  • Market Cap: $56.64M
Additional Links:

Analyst Ratings

Consensus Ratings for Relmada Therapeutics (NASDAQ:RLMDD) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Relmada Therapeutics (NASDAQ:RLMDD)
Show:
DateFirmActionRatingPrice TargetDetails
9/3/2015FBR & CoInitiated CoverageMarket Perform$7.00View Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for Relmada Therapeutics (NASDAQ:RLMDD)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Relmada Therapeutics (NASDAQ:RLMDD)
Current Year EPS Consensus Estimate: $-1.40 EPS
Next Year EPS Consensus Estimate: $-2.11 EPS

Dividends

Dividend History for Relmada Therapeutics (NASDAQ:RLMDD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Relmada Therapeutics (NASDAQ:RLMDD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Relmada Therapeutics (NASDAQ:RLMDD)
DateHeadline
News IconOrphan Drug Designations and Approvals for 2016 (NASDAQ:RLMDD)
www.raredr.com - September 9 at 6:42 PM
4-traders.com logoRELMADA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) (NASDAQ:RLMDD)
www.4-traders.com - September 9 at 6:42 PM
News IconDiabetic Neuropathic Pain - Pipeline Review, H2 2016 - New Market Research Report (NASDAQ:RLMDD)
reports.pr-inside.com - September 2 at 12:00 PM
News IconRadioimmunotherapy 2.0: Actinium Sets Eyes on Bone Marrow Transplant and AML with Later-Stage Programs (NASDAQ:RLMDD)
jutiagroup.com - August 18 at 10:09 AM
News IconLearn details of the postoperative pain pipeline market report - identify diverse types of therapeutics under development, H2 2016 (NASDAQ:RLMDD)
www.whatech.com - August 16 at 10:28 AM
hotstocked.com logoRelmada Therapeutics Inc (OTCMKTS:RLMD) Slips Again (NASDAQ:RLMDD)
www.hotstocked.com - June 25 at 10:52 AM
News IconRelmada Therapeutics' d-Methadone gets US FDA orphan drug status for management of PHN (NASDAQ:RLMDD)
www.pharmabiz.com - June 9 at 10:08 AM
News IconAnalysts' Downgrades for April, 14th (DLAR, IWSY, JOB, JRVR, JTPY, JYNT, KHNGY, KNL, LBRDA, LC) - Washington News Wire (NASDAQ:RLMDD)
washingtonnewswire.com - April 14 at 10:10 AM
finance.yahoo.com logoRelmada Therapeutics Announces Issuance of U.S. Patent Covering SECUREL™ - an Abuse-Deterrent, Extended-Release, Technology Platform for Opioids (NASDAQ:RLMDD)
finance.yahoo.com - September 9 at 8:00 AM
finance.yahoo.com logoRelmada Therapeutics to Participate in Two Upcoming Investor Conferences (NASDAQ:RLMDD)
finance.yahoo.com - September 2 at 8:00 AM

Social

Relmada Therapeutics (NASDAQ:RLMDD) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff